Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from PBMC-derive eNK cells was armed and promoted CAR-like response against tumors through armed with 16Fc21, a novel bispecific fusion protein for NK cells. Local targets link to admitted publications; unresolved targets remain external evidence.
Cell therapies in the clinic
10.1002/btm2.10214 · 2021 · External reference
Cell therapy: types, regulation, and clinical benefits
10.3389/fmed.2021.756029 · 2021 · External reference
Adoptive cell transfer as personalized immunotherapy for human cancer
10.1126/science.aaa4967 · 2015 · External reference
Engineered natural killer cells for cancer therapy
10.1016/j.ccell.2025.09.013 · 2025 · External reference
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
10.1038/s41423-020-0488-6 · 2020 · External reference
Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis
10.1016/j.cell.2022.03.030 · 2022 · External reference
Natural killer cell therapies
10.1038/s41586-023-06945-1 · 2024 · External reference
Exploring the NK cell platform for cancer immunotherapy
10.1038/s41571-020-0426-7 · 2021 · External reference
Bringing natural killer cells to the clinic
10.1084/jem.20220830 · 2022 · External reference
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
10.1038/s41573-022-00413-7 · 2022 · External reference
Generating natural killer cells for adoptive transfer: expanding horizons
10.1016/j.jcyt.2020.12.002 · 2021 · External reference
Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML
10.1158/1078-0432.ccr-17-3196 · 2018 · External reference
IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial
10.1038/sj.bmt.1704086 · 2003 · External reference
Treatment of colon and lung cancer patients with ex vivo heat shock protein 70peptide-activated, autologous natural killer cells: a clinical phase I trial
10.1158/1078-0432.ccr-03-0683 · 2004 · External reference
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
10.3109/14653249.2010.515582 · 2011 · External reference
Harnessing innate immunity in cancer therapy
10.1038/s41586-019-1593-5 · 2019 · External reference
NK cell-based immunotherapy for cancer
10.1016/j.smim.2017.07.009 · 2017 · External reference
NK cell-based cancer immunotherapy from basic biology to clinical development
10.1186/s13045-020-01014-w · 2021 · External reference
Natural killer cell-based immunotherapy for acute myeloid leukemia
10.1186/s13045-020-00996-x · 2020 · External reference
Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation
10.1182/blood-2017-05-785659 · 2017 · External reference
Understanding the tumor immune microenvironment (TIME) for effective therapy
10.1038/s41591-018-0014-x · 2018 · External reference
Strategies to augment natural killer (NK) cell activity against solid tumors
10.3390/cancers11071040 · 2019 · External reference
Overcoming resistance to natural killer cell based immunotherapies for solid tumors
10.3389/fonc.2019.00051 · 2019 · External reference
Natural killer cells in antitumour adoptive cell immunotherapy
10.1038/s41568-022-00491-0 · 2022 · External reference
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
10.18632/oncotarget.13411 · 2016 · External reference
Mechanisms of natural killer cell-mediated cellular cytotoxicity
10.1002/jlb.mr0718-269r · 2019 · External reference
The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses
10.3389/fimmu.2012.00402 · 2013 · External reference
Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies
10.1182/blood-2007-11-122465 · 2008 · External reference
Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells
10.1084/jem.167.2.452 · 1988 · External reference
Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor
10.1080/2162402x.2017.1312045 · 2017 · External reference
Role of distinct natural killer cell subsets in anticancer response
10.3389/fimmu.2017.00293 · 2017 · External reference
IL-21 induces the functional maturation of murine NK cells
10.4049/jimmunol.172.4.2048 · 2004 · External reference
Interleukin-21 activates human natural killer cells and modulates their surface receptor expression
10.1111/j.1365-2567.2007.02730.x · 2008 · External reference
Interleukin-21 increases direct cytotoxicity and IFN-γ production of ex vivo expanded NK cells towards breast cancer cells
2012 · External reference
Interleukin-21 enhances NK cell activation in response to antibody-coated targets
10.4049/jimmunol.177.1.120 · 2006 · External reference
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD
10.1016/j.ccell.2024.07.007 · 2024 · External reference
CAR-NK for tumor immunotherapy: clinical transformation and future prospects
10.1016/j.canlet.2019.11.033 · 2020 · External reference
Cancer immunotherapy based on natural killer cells: current progress and new opportunities
10.3389/fimmu.2019.01205 · 2019 · External reference
Development of IL-15/IL-15Ralpha sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives
10.1186/s12934-021-01605-3 · 2021 · External reference
Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID β2mnull mice
10.1016/j.exphem.2007.06.007 · 2007 · External reference
NK cells for cancer immunotherapy
10.1038/s41573-019-0052-1 · 2020 · External reference
NK cell exhaustion
10.3389/fimmu.2017.00760 · 2017 · External reference
Natural killer cells and other innate lymphoid cells in cancer
10.1038/s41577-018-0061-z · 2018 · External reference
Signal transduction in natural killer cells
10.1007/3-540-27743-9_2 · 2006 · External reference
Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy
10.3389/fimmu.2015.00601 · 2015 · External reference
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
10.1186/s13045-021-01083-5 · 2021 · External reference
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
10.1182/blood-2004-12-4797 · 2005 · External reference
Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity
10.1016/j.stem.2018.06.002 · 2018 · External reference
Breakthrough of solid tumor treatment CAR-NK immunotherapy
10.1038/s41420-024-01815-9 · 2024 · External reference
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
10.1038/s41590-020-0728-z · 2020 · External reference
The cancer–natural killer cell immunity cycle
10.1038/s41568-020-0272-z · 2020 · External reference
Development of an antibody-ligand fusion protein scFvCD16A(-)sc4-1BBL in Komagataella phaffii with stimulatory activity for Natural Killer cells
10.1186/s12934-023-02082-6 · 2023 · External reference
Anti-tumor activity of expanded PBMC-derived NK cells by feeder-free protocol in ovarian cancer
10.3390/cancers13225866 · 2021 · External reference
In vitro anti-cancer potentiality of quince and dandelion leaves extract against leukemia cell lines and database retrieval expression of BCR ABL and TCR genes in leukemia
10.34172/ipp.2025.41730 · 2026 · External reference
Mouse xenograft model for intraperitoneal administration of NK cell immunotherapy for ovarian cancer
10.1007/978-1-4939-3684-7_23 · 2016 · External reference
